GET A PIECE OF SAEBO
Leaders in Home Stroke Recovery
$592,631.09 Raised
REASONS TO INVEST
Stroke is the #1 cause of long-term disability with a market size that is projected to double between 2010 and 2050.
As healthcare costs skyrocket, Saebo’s affordable home-based rehabilitation products improve patient recoveries while lowering the short- and long-term costs of care.
A proven track record with 17 patents awarded, a network spanning six continents and over 40 countries, and $44 million in net revenue to date.
Leaving no patient behind
Saebo is dedicated to bringing accessible, affordable, mobility solutions to all. Committed to “leaving no patient behind” Saebo sets out to create products that could benefit every patient. Saebo’s revolutionary product offering is based on the latest advances in rehabilitation research. From the SaeboFlex to the SaeboMAS, Saebo provides innovative and affordable rehabilitation products.
Saebo has grown into a leading global provider of rehabilitative products created through unrelenting leadership and a strong network of clinicians around the world. As we help over 600,000 clients regain function, we aim to make our newest products more accessible than ever.
The Problem
Stroke rehabilitation equipment is overpriced, ineffective, or too complicated for home use
Every 2.1 seconds, someone in the world suffers a stroke. For those who are lucky enough to survive, overcoming paralysis can take months or even years of intense therapy.
Too often, patients are treated in facilities that do not offer the latest advances in stroke rehabilitation technology. Then, they are often sent home with no effective home program and without the tools and resources they need to recover. Most at home stroke rehabilitation technology is overpriced, ineffective, or too complicated for home use.
All along the way, doctors routinely misinform stroke patients about the potential for additional recovery. Many patients are told that they have reached a recovery “plateau” and additional progress is no longer possible.
Without help, patients experience worsening paralysis, decreased range-of-motion, increased pain and depression, and a deteriorating quality-of-life.
Making matters worse, even in developed countries like the U.S., insurance rarely covers the cost of long-term therapy or innovative rehabilitation products.
The latest research demonstrates that it doesn’t have to be this way. Today, we now know that recovery can continue for many years, even decades, but only if patients get the help they need.
The Solution
Providing effective and affordable rehabilitation products delivered directly to the patient’s home
Saebo creates effective, safe, and affordable products allowing every patient to maximize their neurological recovery, from the clinic to the home.
Each of our exclusive, easy-to-use products is designed and vetted by experienced, practicing clinicians.
Our products are backed by years of clinical research and designed for simple use at home.
Our FDA approved and non-invasive devices are affordable, even to those without insurance coverage.
Our portfolio of products help stroke patients overcome a variety of impairments and maximize their recovery.
We have a product or service for every patient looking to improve their recovery at home.
And, because our products are guaranteed to be effective, affordable, and easy-to-use, patients can order any product on our website and enjoy a 30-Day Money-Back Guarantee. We also provide a free evaluation, expert advice, and follow-up clinical support with each order.
gif
Our Traction
Saebo is a trusted brand with global reach
Our lifetime net revenue is at over $44 million and we’ve seen tremendous growth to-date across our B2B and B2C sectors:
A distributor network spanning 6 continents and over 40 countries
17 Patents: our innovative product designs have been awarded 17 different patents by the US Patent Office
FDA clearance: our products has already satisfied FDA pre-marketing requirements or are regulated as class I devices, which are exempt from premarket requirements
Global adoption: Our products have been used by an estimated 800,000 patients in more than 4,000 hospitals around the world.
Additionally, our products are recommended by the 10 top rehabilitation hospitals in the US (as ranked by US News and World Report). Our products and treatment approaches have now been featured in 20 different medical textbooks and publications, authored by the top neurologists and professors around the world. Saebo products and programs are featured in numerous university curriculums around the world.
Our very first product, the SaeboFlex, was recently put on permanent display at the London Science Museum alongside other breakthrough medical technologies such as penicillin and the first MRI.
The Business Model
A multi-channel distribution system, secured with high lifetime value
With over $44 million in net revenue to date, Saebo has a well-established multi-channel business model.
We sell products directly to the end-user through our D2C e-commerce platform. This platform leverages clinical expertise, producing educational content that generates over 250,000 website visits per month. This has paved the way for our significant digital footprint.
Another primary revenue stream is our B2B channel. We sell products directly to hospitals and treatment centers for use in the care of their patients.
We also sell our products through various domestic and international healthcare providers and medical product distributors. This hybrid approach leverages a wide network of international distributors, who can then leverage their insurance networks and/or provider networks to navigate local compliance and logistics issues.
We have seen steady growth to-date across all of these channels:
90% compound annual growth rate (CAGR) for products sold to US patients through our ecommerce platform since 2017.
27% compound annual growth rate (CAGR) for direct-to-patient unit product sales between 2013 and 2018.
10% compound annual growth rate (CAGR) for equipment sold to hospitals between 2013 and 2018.
And our multi-channel approach is now delivering scalable, capital-efficient growth opportunities based on falling customer acquisition costs and increasing customer lifetime values. Our current cost-per-acquisition is around $45 and our estimated lifetime value is about $300 per customer and rising.
The Market
Stroke is the #1 cause of long-term disability worldwide
Saebo is a well-established leader in the neurorehabilitation market for a significant population of stroke survivors:
- Globally, there are over 15 million stroke survivors (source).
- The U.S. alone is home to over 6.4 million stroke survivors with another 800,000 new survivors every year (source).
- Between 2010 and 2050 the number of strokes in the U.S. is projected to double (source).
- By 2030, almost 4% of US adults will have had a stroke (source).
- Roughly 70% of stroke survivors are 65 or older; one of the fastest-growing demographics in the developed world (source).
- Stroke is the number one cause of long-term adult disability worldwide (source).
- The total direct annual stroke-related medical costs are projected to increase from $71 billion in 2012 to $183 billion by 2030 (source).
Consistent, long-term growth in the worldwide market for stroke rehabilitation products will be driven by a number of factors including:
- Increasing stroke incidence levels due to changing demographics and lifestyles (as people live longer, they are more likely to have a stroke at some point in their lives).
- Increasing stroke survival rates due to advances in acute medical care (growing number of survivors means more require post-stroke rehabilitation).
- Increasing demand for new technologies due to advances in neuroscience (new evidence on cortical plasticity is demonstrating that old approaches to treatment are no longer adequate)
And finally, with COVID-19, we have seen an increased incidence of stroke. Particularly with pandemic restrictions, there is an increased urgency and demand for effective in-home therapy.
What we do
Improving stroke rehab: Reimagining what’s possible.
From hospital to home, our products and services support patients each step of the way. Our patient-targeted solutions are designed to meet three simple criteria:
- Proven Efficacy: every product we sell is based on treatment principles backed by science and years of clinical research
- Affordability: we focus on making every product we sell as affordable as possible; in fact, we even have several products and services that we offer for free!
- Ease-of-use: our products are vetted by clinicians with years of hands-on experience helping patients in real-world settings
We also devote many of our resources to educating patients and clinicians around the world about the latest advancements in treatment and how our products incorporate those treatment paradigms.
Saebo Academy is approved by the American Occupational Therapy Association to provide accredited continuing education courses to clinicians. To date, more than 20,000 therapists have participated in our educational programs worldwide.
Our technology and ever-expanding product base continue to grow, with 17 existing patents, demonstrating our unique and innovative technologies.
Saebo has been a worldwide leader in stroke rehabilitation since 2004 and continues to lead the way for patient recovery-focused solutions.
The Vision
A Helping Hand For Every Patient
At Saebo, we believe every patient deserves a helping hand. That means empowering patients with the education, tools, and financial assistance they need to take control of their own recovery.
Today, Saebo is considered by many to be the foremost leader in stroke rehabilitation. Tomorrow, we look forward to bringing our expertise to an ever-expanding range of neurological conditions and impairments.
The stroke survivor population is only the beginning. We also help treat veterans with traumatic brain injuries at VA centers across the country. Millions suffering from Multiple Sclerosis, neuropathy, and other neurological disorders could benefit from our technology.
OUR LEADERSHIP
Decades of Diverse Expertise
With a combined 112 years of clinical experience and 49 years of management experience, the Saebo team is made up of exceptional leaders in business and medicine, poised to change the lives of patients around the world.
Why Invest
We’ve helped about 1 million stroke patients worldwide. 79 million to go.
To continue to provide life-changing solutions for those suffering from impaired mobility and function, Saebo aims to expand global partnerships and provide directly accessible devices for every patient who needs them.
We hope to follow our momentum with funding from StartEngine for new product development, lower-cost product sourcing, a sophisticated DTP digital marketing platform, and additional domestic and international distribution channels and partners. We hope you will join the charge to provide innovative, affordable, and positively impactful solutions so that no patient is ever left behind.
gif
ABOUT
HEADQUARTERS
2459 Wilkinson Blvd. Ste 120-B
Charlotte, NC 28208
WEBSITE
View Site
Saebo’s award-winning rehabilitation products offer stroke survivors a second chance to overcome paralysis and regain quality-of-life. Designed specifically for ease-of-use and affordability, Saebo’s products are targeted to unlock the vast untapped market for in-home neurorehabilitation.
TEAM
Henry Hoffman
Co-Founder and President
As an occupational therapist, Henry has worked in a variety of clinical settings including home health, acute, sub-acute, and outpatient rehab. Prior to leaving Burke Rehabilitation Hospital in New York in 2002, he worked as a clinical specialist in stroke and orthopedic medicine and manual therapy of the upper quadrant. After leaving Burke, Henry co-founded Saebo, with the goal of creating innovative and life-changing solutions for the physically impaired population. He currently holds 17 patents with products that have helped tens of thousands of clients regain function. Saebo's name is an acronym for Henry’s grandmother "Sarah Eileen Booth". Her entire life was dedicated to providing a hand to others in need. Saebo’s mission is to match her spirit, dedication, and desire to help others.
Todd D. Wiebusch
Executive Chairman
Peter Durand
CEO
Pete went on to form Cruxible Partners, a boutique consulting and talent acquisition firm in 2018. After consulting with Saebo, Inc. he joined the company as CEO in early 2022. Pete was excited to marry his passion for health and Saebo’s mission to leave no stroke patient behind.
He is patent holder, a podcast host, an accomplished triathlete, exercise junkie, nutrition nut and NASM Certified Personal Trainer (CPT). Pete holds a BS in Industrial Engineering and MBA and is a former Ernst & Young Entrepreneur of the Year for the Carolinas.
Alan Zdyb
VP Finance
Christopher Klett
Chief Operating Officer
With a passion for early-stage companies, Chris joined Saebo in its first year of operations and has enjoyed overseeing the back-office, warehouse and distribution operations, while also directing the reimbursement, compliance, and marketing strategies as Saebo's full-time COO. Prior to joining Saebo, Chris built his experience in the healthcare sector as Director of Mergers and Acquisitions for CHMG Capital. Chris received his BA in Economics from Davidson College.
Sean Jones
Director of Supply Chain
Sean has worked in the manufacturing/production field for over 20 years and has been with Saebo for the last 10 years. Before joining Saebo he ran three manufacturing plants at one time for a Multinational craft company. While attending college for a business degree in management, he started working in the plants learning the different tasks in various departments from the bottom up. This has given him a solid foundation consisting of academic knowledge as well as hands-on experience.
Dr. Scott Thompson
Director of Clinical Services
A seeker of knowledge, Scott holds Masters and Doctorate degrees in Occupational therapy, with advanced certifications in neurological treatment. While he is a full time (40 hours/week) employee of Saebo, he also participates in professional duties by holding advisory board positions for two occupational therapy schools and sits as an executive board member of his state’s occupational therapy association and foundation.
Dr. Steve Wolf
Advisory Board Member
Dr. Wolf’s professional contributions include establishing the inclusion criteria for forced use of the upper extremity following stroke and contributing to the formulation of what later became known as constraint-induced movement therapy, establishing Tai Chi as a falls’ prevention exercise for older adults, and helping to establish what is today known as the FiRST (Frontiers in Rehabilitation Science and Technology) Council of the APTA. Considered by some to be a bit of a visionary, he has received honors from multiple professional organizations, has authored or co-authored over 270 refereed articles; edited 9 books; procured over $70M in grant funding; and has provided over 800 national and international lectures.
Dr. Wolf spends up to approximately 5 hours per month, as needed, consulting with Saebo on education topics, product development and industry trends.
Glyn Blakey
Managing Director, SaeboUK
Glyn has worked with the National Health Service and private practice as a clinical specialist in stroke rehabilitation. He now enjoys his active managing director role as an educator within the stroke rehabilitation industry. He has played a pivotal role is setting up the European Saebo distributorships.
Amy Bean
Clinical Specialist
Amy has grown her clinical experience in a variety of locations within the National Health Service in the UK, and also in private health care in Australia. Her switch to working with Saebo for the last 11 years comes from seeing the significant difference in rehabilitation outcomes using the Saebo range in her previous clinical role in Stroke Rehabilitation.
TERMS
Saebo
Overview
PRICE PER SHARE
$0.50
DEADLINE
Jun 1, 2022
VALUATION
$10.96M
FUNDING GOAL
$10k - $1.07M
Breakdown
MIN INVESTMENT
$248
MAX INVESTMENT
$24,999.50
MIN NUMBER OF SHARES OFFERED
20,000
MAX NUMBER OF SHARES OFFERED
2,139,998
OFFERING TYPE
Equity
ASSET TYPE
Common Stock
SHARES OFFERED
Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Votings Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the President of the Company (the “President”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the President determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the President for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives and Bonuses*
Time-Based:
Friends and Family Early Birds
Invest within the first 48 hours and receive an additional 20% bonus shares.
Super Early Bird Bonus
Invest within the first week and receive an additional 15% bonus shares.
Early Bird Bonus
Invest within the first two weeks and receive an additional 10% bonus shares.
Amount-Based:
$500+
Supporter Level
Supporters will receive a $25 gift card for the products or swag of your choice at saebo.com. You’ll also receive a personalized coupon code to save 20% on any product of your choice.*
$1,000+
Bronze Investor Level
Bronze Investors will receive a $50 gift card for the products or swag of your choice at saebo.com. You’ll also receive a coupon code to save 20% on your entire next order.*
$2,500+
Silver Investor Level
Silver Investors will receive a $100 gift card for the products or swag of your choice at saebo.com. You’ll also receive a personalized coupon code to save 20% on all of your orders for an entire year.*
$5,000+
Gold Investor Level
Gold Investors will receive 10% Bonus Shares plus all of the Silver Level perks. In addition, Saebo will donate, in your name, $500 worth of products to patients in need.
$10,000+
Platinum Investor Level
Platinum Investors will receive 15% Bonus Shares plus all of the Silver Level perks. In addition, Saebo will donate, in your name, $1,000 worth of products to patients in need.
*Excludes hospital-based treatment equipment (e.g., items priced over $5,000).
*All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Saebo, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $0.50 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $50. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Irregular Use of Proceeds
We will not incur any irregular use of proceeds.
PRESS
ALL UPDATES
REWARDS
JOIN THE DISCUSSION
0/2500
PINNED BY STARTUP
Bradley Short
3 years ago
As a Physiatrist and in practice for over 28 years, I am quite familiar with those inflicted with strokes...
I am also familiar with SAEBO products...
They are revolutionary and truly excellent.
1
5
Diana Priego
9 months ago
I am also waiting for my rewards too? My son uses your products.
0
0
William Larsen
a year ago
I'm am a stroke survivor & use many Saebo products. I love your products which have helped in my recovery. This is one of a number of reasons why I invested in Saebo. When will I receive my investment incentives? I am looking at purchasing more Saebo products very soon. Looking forward to your reply.
Thanks! Bill Larsen
2
0
Troy Gibson
a year ago
Troy G. Here. question, my investment/shares in Saebo. If something were to happen to me will my shares go to a beneficiary. How does this work ?
Thanks
0
0
Manuel Marques
a year ago
Good afternoon,
I invested during the December campaign and am now looking to place an order for my mother. Where would I locate the coupon code/discount code for my investor level perk?
Thank you in advance.
1
0
Manuel Morales Wyden
a year ago
Hello! Is it still not possible to make an investment outside of the U.S.? - would be very interested in doing so - keep up the good work and thanks for the reply!
0
0
Steve Mills
a year ago
What has been the response from the insurance industry? I saw a statement..."affordable even without insurance." How much of what you offer is covered under an average insurance plan? Would/could these aids be covered under Medicare? It seems to me, if this can save the insurance companies money, they'll be a major influence in scaling the company.
1
0
Adam Forster
2 years ago
Does the new Saebostim Spa help w foot pain from neuropathy? Product looks nice. Great work. Thanks.
2
0
Paul Tuscano
2 years ago
The product sound great and it seems like you are doing well. I am curious what you need the funding for? I saw a response below saying that you were going to develop newer products. I would think you would want to optimize the margins and volumes sold of the existing products before pursuing other products. If profitability is a concern despite having good products which are defensible then you have an operating model problem and need to focus. You might want to consider cutting back or pausing some of your other products which might be less successful and carry a higher operating cost.
1
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
PINNED BY STARTUP
Denise Colella
3 years ago
1
2